Last reviewed · How we verify
Radspherin
Radspherin is a Small molecule drug developed by Oncoinvent Solutions AS. It is currently in Phase 2 development.
Radspherin is being studied in clinical trials for the treatment of Peritoneal Carcinoma, Colorectal Carcinoma, Peritoneal Carcinomatosis, and Ovarian Cancer. It is being evaluated in a Phase 1/2a study for its safety and efficacy in treating Colorectal Carcinoma subjects with Peritoneal Carcinomatosis who have undergone HIPEC (Hyperthermic Intraperitoneal Chemotherapy).
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Radspherin |
|---|---|
| Sponsor | Oncoinvent Solutions AS |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery (PHASE2)
- Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC (PHASE1, PHASE2)
- Study of Radspherin® in Recurrent Ovarian Cancer Subjects With Peritoneal Carcinomatosis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Radspherin CI brief — competitive landscape report
- Radspherin updates RSS · CI watch RSS
- Oncoinvent Solutions AS portfolio CI
Frequently asked questions about Radspherin
What is Radspherin?
Who makes Radspherin?
What development phase is Radspherin in?
Related
- Manufacturer: Oncoinvent Solutions AS — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing